213 results
The primary objective is to assess the impact of hyperhydration on pemetrexed pharmacokinetics. The secondary objective is to compare the performance of different renal function algorithms to predict pemetrexed pharmacokinetics.
To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and…
The aim of the study is to create and optimize a DWI MRI scan protocol to assess thymic masses.
The objective of this study proposal is to investigate whether use of biomarkers (intracellular pemetrexed levels and/or geneticloci) for response and toxicity to pemetrexed improves the effectiveness of therapy and cost-effectiveness ratio. This…
The goal of this study is to investigate the feasibility of the integration of an EMTS in a standard clinical EUS setting.
The primary objective of this study is to estimate the best objective response rates (ORR; complete response [CR] + partial response [PR]) associated with gemcitabine-cisplatin plus necitumumab in chemotherapy-naïve patients with Stage IV squamous…
To study the effect of surgery and SABR on both immunostimulatory (with primary endpoint CD8 positive cells)and immunosuppressive cells in peripheral blood in patients with early stage non-small cell lung cancer who are treated with either modality.
Primary objective is to analyse whether transnasal videolaryngoscopy in outpatient practice is more accurate in determination of the extend of the affected mucosa of laryngopharyngeal tumours compared to direct laryngoscopy under general anaesthesia…
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To investigate the dynamics of tumour hypoxia as assessed by 18F-FAZA PET/CT during and after chemoradiotherapy. To investigate the best strategy to deliver a boost dose to the hypoxic tumour areas. This strategy may be either a simultaneous boost (…
To determine the influence of the acidic beverage Coca-Cola, concomitantly taken with erlotinib (with or without a PPI), on erlotinib plasma pharmacokinetics compared to erlotinib concomitantly taken with water in cancer patients.
The primary objective of this trial is to assess the effectiveness of IG-SBRT in patients with medically inoperable early stage, centrally located NSCLC and in those who are not willing to undergo surgical treatment.The primary measure of…
Identification of protein profile differences between laryngeal cancer of young and elderly patients. Secondary objective is to identify differences between protein interaction network in cancer and healthy tissue in young and elderly laryngeal…
RO5479599 is an experimental drug under investigation by F. Hoffmann-La Roche for the treatment of solid tumors with a HER3 over-expressed, in this study focused on patients with advanced / metastatic non-small cell lung cancer (NSCLC) of squamous…
The aim of this study is to evaluate the efficacy of a personalized drug profiling method using short-term cultures of malignant cells derived from the patient*s pleural fluid.
To determine if FDG PET/CT is performant enough with respect to detecting residual lymph node involvement after chemoradiation in order to omit planned neck dissections in patients with locally advanced potentially operable, N2 and N3 head and neck…
i. Primary endpointTreatment toxicity in terms of acute or late grade 2-4 esophageal and pulmonary adverse events, or other grade 2-4 adverse events (RTOG Acute Radiation Morbidity Scoring Criteria and RTOG/ESTRO Late Radiation Morbidity Scoring…
The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and…
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
The aim of this research is to gain a more detailed insight into the illness perceptions of patients with lung cancer. With this insight it is our aim to improve biopsychosocial care for these patients. Research question: What are the illness…